Arsenic trioxide regulates DYNAP through hsa-mir-573 and inhibits the proliferation of laryngeal cancer.

ABSTRACT: Laryngeal squamous cell carcinoma (LSCC) is a malignant tumor with limited treatment options and poor prognosis in advanced stages. Arsenic trioxide (ATO), a drug well-known for treating acute promyelocytic leukemia, has shown potential antitumor effects in several solid tumors. This study aimed to investigate the role of ATO on LSCC proliferation and its underlying molecular mechanisms. LSCC cell lines (TU212, TU686, and AMC-HN-8) were treated with varying concentrations of ATO, and cell proliferation was evaluated using CCK-8, colony formation, and EdU assays. miRNA-sequencing identified differentially expressed miRNAs after ATO treatment, and bioinformatics tools predicted hsa-miR-573 target genes. The interaction between hsa-miR-573 and dynactin-associated protein (DYNAP) was validated

SUBMITTER: Ren Y 

PROVIDER: S-EPMC12304475 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature